ALIVUSAlivus Life Sciences Ltd.
Alivus Life Sciences acquires 65.01% of IQGEN-X Pharma, which becomes a subsidiary
The remaining share capital will be acquired in due course, the company said. The consideration and the business IQGEN-X carries on are not stated in the filing.
- Mergers & acquisitions
- pharmaceuticals